Login
$REGN
$953.36 +$0.96 (0.1%) After hours

$REGN 8-K/A SEC Filings

Filed On Filing
08 Sep 2023 8-K/A: Submission of Matters to a Vote of Security Holders

At the 2023 Annual Meeting of Shareholders of the Company held on June 9, 2023, Regeneron’s shareholders voted, among other matters, on a proposal on the frequency of future advisory shareholder votes on executive compensation. As report...

07 May 2019 8-K/A: Regulation FD Disclosure

The Company’s updated full year 2019 financial guidance consists of the following components:

13 Sep 2017 8-K/A: Submission of Matters to a Vote of Security Holders

At the 2017 Annual Meeting of Shareholders of the Company held on June 9, 2017, Regeneron’s shareholders voted, among other matters, on a proposal on the frequency of future advisory shareholder votes on executive compensation. As report...

23 May 2014 8-K/A: Unregistered Sales of Equity Securities

As described in Item 1.01 of this Report, which is incorporated herein by reference, on October 21, 2011, the Company issued $400 million aggregate principal amount of Notes to the Initial Purchaser in a private placement pursuant to exe...

24 Jan 2012 8-K/A: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

22 Nov 2011 8-K/A: Other Events

Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration

15 Sep 2011 8-K/A: Submission of Matters to a Vote of Security Holders

At Regeneron’s 2011 Annual Meeting of Shareholders held on June 10, 2011, Regeneron’s shareholders voted on, among other matters, a proposal on the frequency of future advisory shareholder votes on executive compensation. As reported by ...

26 Jan 2001 8-K/A: Other Events

Tarrytown, New York, January 25, 2001 -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its full year and fourth quarter financial and operating results for 2000.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support